Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Liver disease related to obesity and diabetes rising in U.S.

The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.

Read More »

The impact of technology on advancing diabetes care

Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.

Read More »

Lexicon Posts Positive 52-Week Pooled Zynquista Data in Type 1 Diabetes

Shares of Texas-based Lexicon Pharmaceuticals shot up after the company announced positive 52-week cardiorenal data from a pooled analysis of the type 1 diabetes trials Tandem1 and Tandem2.

Read More »

Novo Nordisk’s new diabetes, obesity drugs lift sales outlook

Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.

Read More »

Eli Lilly tops profit estimates on boost from diabetes drugs

Eli Lilly and Co. beat analysts’ estimates for second-quarter 2019 profit and raised the company’s full-year earnings forecast, as higher sales of the diabetes drugs Trulicity and Basaglar offset competition for the erectile dysfunction treatment Cialis.

Read More »

Sanofi Reports Strong Second-Quarter 2019

Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.

Read More »

Sanofi ends partnership with Lexicon to develop diabetes drug

French drugmaker Sanofi SA terminated a partnership with Lexicon Pharmaceuticals Inc. to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.

Read More »

FDA Approves First Needle-Free Glucagon to Treat Severe Hypoglycemia

The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.

Read More »

Abbott to hike production of lower-cost glucose monitors as diabetes soars

Abbott Laboratories plans to ramp up manufacturing capacity for the company’s lower-cost continuous glucose monitor – the FreeStyle Libre – by three to five times in the next few years, aiming to reach millions more patients worldwide.

Read More »

AstraZeneca’s Farxiga fails to receive U.S. approval for type 1 diabetes

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom